AVTRAvantor, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for ~2% a year FCF growth. Little growth is priced in even as revenue fell 4% a year over three years, potential value, or a value trap.
Cheap vs its own history: P/E 13.6 vs a 39.5 median over 20 quarters (−66% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AVTR's price assumes
Today's price asks for 2.4% free cash flow growth a year; over the last three years Avantor, Inc. delivered −17%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.4%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +2.4%
Growth the price implies · The price pays for +2.4% free cash flow growth a year for a decade; the business has delivered −17% a year over the last three.
- Price / book
- 1.23
Price / book · today's price, trailing year to Mar 31, 2026
Details›
- Price / booktoday's price, trailing year to Mar 31, 2026
- 1.23
- EV / EBIToperating margin −4.5%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Mar 31, 2026
- 1.59
- Free cash flow, trailing twelve months
- $439M
- Market capitalisation
- $6.88B
- 3-year revenue growth
- −3.7%
- 3-year free cash flow growth
- −17%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #12 of 21 by RyuScore